Efficacy of Neural Prolotherapy for Treatment of Anserine Bursitis "NPCAB"
Anserine Bursitis
About this trial
This is an interventional treatment trial for Anserine Bursitis focused on measuring Anserine bursitis, Neural prolotherapy, Perineural injection
Eligibility Criteria
Inclusion Criteria:
- Chronic anserine bursitis was based on clinical manifestations, which was the presence of pain in the medial and inferior aspect of the knee. It was increased during going upstairs and downstairs associated with tenderness on the inferomedial aspect of the knee joint about 5 cm below the medial knee joint line and occasionally local swelling. It could be associated with morning pain and stiffness.
- Patients who were refractory to conservative treatment for at least 3 months were considered to have chronic anserine bursitis. Each knee was assessed separately for eligibility.
Exclusion Criteria:
- Symptomatic knee osteoarthritis.
- Internal derangement of the knee.
- Previous knee surgery.
- Prior surgery in the affected knee region.
- Systemic rheumatologic disorders.
- Fibromyalgia.
- Diabetes mellitus.
- Endocrine disorders.
- Metabolic disorders.
- Coagulopathy.
- Anticoagulant treatment.
- Current skin or soft tissue infection at or near the site of injection.
- Prior local soft tissue injection of corticosteroid for anserine bursitis in the past year.
- Prior neural prolotherapy for anserine bursitis in the past year.
- Patients presented with a systemic active inflammatory condition or infection.
- Pregnancy.
- Unwillingness to participate in the study.
- History of allergy to the used corticosteroid and/or local anaesthetic.
Sites / Locations
- Faculty of Medicine, Alexandria University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Neural prolotherapy
Corticosteroid group
Neural prolotherapy using isotonic dextrose 5% in water solution (about 3 ml). The injection was done using Lyftgot technique. The subcutaneous injections were done at sensory nerves fascial penetration points and tender areas around the anserine bursa anatomical region.
Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.